- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05053555
Brachiterapia ad alto dosaggio per il trattamento di neoplasie epatiche primarie e secondarie non resecabili
Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies. These advances have resulted in a myriad of benefits for patients including decreased morbidity, mortality, as well as increased longevity and quality of life. However, these therapies can only be performed within certain parameters. Thermal ablative techniques such as radiofrequency ablation (RFA) and microwave ablation (MVA) are recommended for small lesions under 3 cm due to decreased efficacy when attempting to treat larger lesions. Additionally, large vessels in close proximity to a target lesion may result in heat dissipation, termed the "heat sink" effect, and result in incomplete ablation of the lesion. Furthermore, thermal ablative techniques cause off-target damage when utilized near sensitive structures such as the diaphragm, stomach, or bowel, and if performed near thermosensitive bile ducts, can result in cholestasis . Noting these limitations, percutaneous high-dose-rate brachytherapy was brought into clinical practice by Ricke et al. in Europe in 2002 . This therapy utilizes an iridium-192 (192Ir) isotope to administer a cytotoxic dose of radiation to a target lesion. It is not susceptible to heat sink effects and can also deliver radiation with the precision necessary to cause tumor death without destroying the integrity of neighboring structures. Additionally, it can be used to treat larger tumors (>3cm) as it is not associated the same size limitations as ablative techniques and can also be utilized to treat lesions that are not amenable to intra-arterial therapies (such as trans-arterial chemoembolization and yttrium-90 radioembolization).
Since its inception, HDRBT has been evaluated through multiple studies investigating its use to treat lesions throughout the body including both primary and secondary liver malignancies such as hepatocellular carcinoma (HCC), cholangiocarcinoma, metastasis to the liver from colorectal cancer, pancreatic cancer , melanoma , and breast cancer . Its use in treating lymph node metastases has also been investigated . These studies have demonstrated the feasibility, safety, and clinical effectiveness of this method, establishing it as a therapeutic option when use of thermal ablation therapies is restricted. Most studies however, have been retrospective and have been performed outside the United States.
Studying this therapy will add a crucial treatment option to our current armamentarium, filling a gap in currently available therapies and additionally allowing for further investigation of the use of HDRBT in a larger and more diverse population.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Primary Objective
-To prospectively evaluate the clinical effectiveness of the use of high dose rate brachytherapy (HDRBT) for the treatment of both primary and secondary unresectable liver malignancies assessed by comparing local tumor control (LTC) rates at 6 months with a historical cohort.
Secondary Objectives
- To compare local tumor control rates at 3-month intervals between cohorts for the duration of the study (3 months, 9 months, 12 months, etc.).
- To compare overall survival (OS) and progression-free survival (PFS) between cohorts.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Joshua Kuban
- Numero di telefono: 713-745-0944
- Email: jdkuban@mdanderson.org
Luoghi di studio
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- M D Anderson Cancer Center
-
Investigatore principale:
- Joshua Kuban, MD
-
Contatto:
- Joshua Kuban, MD
- Numero di telefono: (713) 745-0944
- Email: jdkuban@mdanderson.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
GROUP A: Patients with liver lesions must be over the age of 18
-
GROUP A: Any patient with up to five unresectable tumors that are:
- At least 3 cm (largest diameter in the axial plane)
- In close proximity to large blood vessels
- In close proximity to sensitive structures (bowel, stomach, diaphragm, liver capsule, liver hilum, bile ducts)
- Associated with difficult endovascular access to one or more feeding arterial branches (hypovascular tumors)
- Associated with a large shunt fraction to other vital organs
-
GROUP B: Historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021
Exclusion criteria:
- Active infectious disease
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with polymetastatic disease with the exception of those patients who may benefit from therapy addressing local complications directly related to the target lesion diminishing quality of life such as pain, vascular/biliary occlusion, and liver disfunction
- Pregnancy (sexually active patients must be on birth control while participating in this study)
- Child-Pugh class C
- Total serum bilirubin > 2 mg/dl
- Platelet count < 50,000/ul
- International normalized ratio (INR) > 1.5
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Group A (Prospective cohort )
20 patients, will undergo initial diagnostic workup, staging and treatment per institutional standard of care. Intervention: High dose rate brachytherapy (HDRBT) |
diagnostic workup, staging, and treatment per the institution standard of care reviewing historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021 |
|
Sperimentale: Group B( Retrospective chart review )
40 patients who meet same eligibility criteria, but did not receive HDRBT between 1/1/2000 and 1/1/2021. |
diagnostic workup, staging, and treatment per the institution standard of care reviewing historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021 |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Valutare in modo prospettico l'efficacia clinica dell'uso della brachiterapia ad alto dosaggio (HDRBT) per il trattamento di entrambe le neoplasie epatiche primarie.
Lasso di tempo: Attraverso il completamento degli studi, una media di 1 anno
|
Attraverso il completamento degli studi, una media di 1 anno
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Joshua Kuban, M.D. Anderson Cancer Center
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Neoplasie delle ghiandole endocrine
- Malattie pancreatiche
- Malattie del fegato
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Neoplasie del fegato
- Malattie della pelle
- Carcinoma
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Tumori neuroendocrini
- Nevi e melanomi
- Neoplasie cutanee
- Malattie della pelle e del tessuto connettivo
- Carcinoma, epatocellulare
- Neoplasie pancreatiche
- Melanoma
Altri numeri di identificazione dello studio
- 2020-1255
- NCI-2021-09408 (Altro identificatore: Clinical Trials Reporting Program (CTRP))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .